Proton therapy and the European Particle Therapy Network: The past, present and future

D C Weber, J A Langendijk, C Grau, J Thariat, D C Weber, J A Langendijk, C Grau, J Thariat

Abstract

Proton therapy is delivered to selected cancer patients presenting with rare tumours, for which a dose escalation paradigm and/or a reduced dose-bath to the organs at risk is pursued. It is a costly treatment with an additional cost factor of 2-3 when compared to photon radiotherapy. Notwithstanding the 180'000 patients treated with protons, scars robust clinical evidence is available to justify the administration of this treatment modality. The European Particle Therapy Network (EPTN) was created in 2015 to answer the critical European needs for cooperation among protons and carbon ions centres in the framework of clinical research networks. EPTN with other European groups will launch a number of prospective clinical trials that could be practice changing if positive. Alternative way to generate clinical data could be provided by alternative methodologies, such as the Dutch model-based approach, or could be provided by European infrastructure projects.

Keywords: Cancer; EPTN; European research infrastructure; European research networks; Infrastructures de recherche européennes; Proton therapy; Protonthérapie; Réseaux de recherche clinique européens.

Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

References

    1. Su Z., Indelicato D.J., Mailhot R.B., Bradley J.A. Impact of different treatment techniques for pediatric Ewing sarcoma of the chest wall: IMRT, 3DCPT, and IMPT with/without beam aperture. J Appl Clin Med Phys. 2020;21:100–107.
    1. Wilson R.R. Radiological use of fast protons. Radiology. 1946;47:487–491.
    1. Lawrence J.H. Proton irradiation of the pituitary. Cancer. 1957;10:795–798.
    1. Weber D.C., Abrunhosa-Branquinho A., Bolsi A., Kacperek A., Dendale R., Geismar D., et al. Profile of European proton and carbon ion therapy centers assessed by the EORTC facility questionnaire. Radiother Oncol. 2017;124:185–189.
    1. Goitein M., Jermann M. The relative costs of proton and X-ray radiation therapy. Clin Oncol (R Coll Radiol) 2003;15:S37–S50.
    1. Weber D.C., Habrand J.L., Hoppe B.S., Hill Kayser C., Laack N.N., Langendijk J.A., et al. Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN. Radiother Oncol. 2018;128:44–55.
    1. Lundkvist J., Ekman M., Ericsson S.R., Isacsson U., Jonsson B., Glimelius B. Economic evaluation of proton radiation therapy in the treatment of breast cancer. Radiother Oncol. 2005;75:179–185.
    1. Lundkvist J., Ekman M., Ericsson S.R., Jonsson B., Glimelius B. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer. 2005;103:793–801.
    1. Lundkvist J., Ekman M., Ericsson S.R., Jonsson B., Glimelius B. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol. 2005;44:850–861.
    1. Hirano E., Fuji H., Onoe T., Kumar V., Shirato H., Kawabuchi K. Cost-effectiveness analysis of cochlear dose reduction by proton beam therapy for medulloblastoma in childhood. J Radiat Res. 2014;55:320–327.
    1. Konski A., Speier W., Hanlon A., Beck J.R., Pollack A. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol. 2007;25:3603–3608.
    1. Goitein M. Trials and tribulations in charged particle radiotherapy. Radiother Oncol. 2010;95:23–31.
    1. Goitein M., Cox J.D. Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol. 2008;26:175–176.
    1. Langendijk J.A., Boersma L.J., Rasch C.R.N., van Vulpen M., Reitsma J.B., van der Schaaf A., et al. Clinical trial strategies to compare protons with photons. Semin Radiat Oncol. 2018;28:79–87.
    1. Grau C., Durante M., Georg D., Langendijk J.A., Weber D.C. Particle therapy in Europe. Mol Oncol. 2020 doi: 10.1002/1878-0261.12677.
    1. Grau C., Baumann M., Weber D.C. Optimizing clinical research and generating prospective high-quality data in particle therapy in Europe: introducing the European Particle Therapy Network (EPTN) Radiother Oncol. 2018;128:1–3.
    1. Thomas G., Eisenhauer E., Bristow R.G., Grau C., Hurkmans C., Ost P., et al. The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting report. Eur J Cancer. 2020;131:76–88.
    1. Weber D.C., Grau C., Lim P.S., Georg D., Lievens Y. Bringing Europe together in building clinical evidence for proton therapy–the EPTN-ESTRO-EORTC endeavor. Acta Oncol. 2019:1–3.
    1. Langendijk J.A., Orecchia R., Haustermans K., Zips D., Balosso J., Lacombe D., et al. Prospective data registration and clinical trials for particle therapy in Europe. Radiother Oncol. 2018;128:9–13.
    1. Langendijk J.A., Lambin P., De Ruysscher D., Widder J., Bos M., Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107:267–273.
    1. Sakso M., Andersen E., Bentzen J., Andersen M., Johansen J., Primdahl H., et al. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. Acta Oncol. 2019;58:1495–1501.
    1. Price J., Hall E., West C., Thomson D. TORPEdO–A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer. Clin Oncol (R Coll Radiol) 2020;32:84–88.
    1. Rwigema J.M., Langendijk J.A., Paul van der Laan H., Lukens J.N., Swisher-McClure S.D., Lin A. A model-based approach to predict short-term toxicity benefits with proton therapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2019;104:553–562.
    1. Stick L.B., Yu J., Maraldo M.V., Aznar M.C., Pedersen A.N., Bentzen S.M., et al. Joint estimation of cardiac toxicity and recurrence risks after comprehensive nodal photon versus proton therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2017;97:754–761.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren